chitosan has been researched along with hydroxypropylmethylcellulose acetate succinate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Araújo, F; Granja, PL; Herranz-Blanco, B; Hirvonen, JT; Liu, D; Mäkilä, EM; Salonen, JJ; Santos, HA; Sarmento, B; Shahbazi, MA; Shrestha, N | 1 |
| Airavaara, M; Araújo, F; Gomes, MJ; Hirvonen, J; Kauppinen, EI; Mäkilä, E; Raula, J; Salonen, J; Santos, HA; Sarmento, B; Shahbazi, MA; Shrestha, N | 1 |
2 other study(ies) available for chitosan and hydroxypropylmethylcellulose acetate succinate
| Article | Year |
|---|---|
Microfluidic Assembly of a Multifunctional Tailorable Composite System Designed for Site Specific Combined Oral Delivery of Peptide Drugs.
Topics: Caco-2 Cells; Cell Survival; Cell-Penetrating Peptides; Chitosan; Coculture Techniques; Dipeptidyl Peptidase 4; Drug Compounding; Drug Delivery Systems; Drug Liberation; Drug Synergism; Glucagon-Like Peptide 1; HT29 Cells; Humans; Hydrogen-Ion Concentration; Kinetics; Methylcellulose; Microfluidics; Nanoparticles; Permeability; Polyglactin 910; Porosity; Silicon | 2015 |
Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model.
Topics: Administration, Oral; Animals; Blood Glucose; Chitosan; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Intestine, Small; Methylcellulose; Nanocomposites; Nanoparticles; Rats, Wistar; Silicon | 2016 |